Innolake Biopharm
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biopharma developing antibody and fusion protein therapies for oncology and immunology.
OncologyImmunology
Technology Platform
Biologics discovery and development platform focused on monoclonal antibodies and fusion proteins for immune-mediated diseases and cancer.
Opportunities
Successful launch of its late-stage assets in China's large and growing biologics market could establish it as a major commercial player.
Risk Factors
Late-stage clinical trial failures or unfavorable pricing decisions by Chinese health authorities could severely impact revenue projections and profitability.
Competitive Landscape
Positioned as a leading domestic innovator in biologics, facing competition from multinational pharma giants and a crowded field of similar Chinese biotechs.